GSK targets neurodegenerative diseases with latest licensing deal
The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...
The Pharma Letter17h
ABL Bio leaps as it announces deal with GSK
South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK ...
Contract Pharma12h
ABL Bio and GSK to Develop Medicines for Neurodegenerative Diseases
Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.
Australian Associated Press19h
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology t ...
PMLive20h
GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn
GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases.